During the three and six months ended June 30, 2026, we recognized $0.4 million and $0.9 million, respectively, of compensation expense associated with stock option and restricted stock awards granted in years 2021 through 2025. During the three and six months ended June 30, 2025, we recognized $0.4 million and $0.8 million, respectively, of compensation expense associated with stock option and restricted stock awards granted in years 2020 through 2024.

The following table summarizes our stock option activity for the six-month period ended June 30, 2026:


				Weighted
		Weighted		Average	Aggregate
		Average		Remaining	Intrinsic
		Exercise		Contractual	Value*
Stock Options	Shares	Price		Term (In Years)	(In Thousands)
Outstanding at January 1, 2026	512,705	$	26.15
Granted	—		—
Exercised	(9,980)		25.54
Forfeited or expired	(5,550)		29.28
Outstanding at June 30, 2026	497,175	$	26.12	4.9	$	6,566
Exercisable at June 30, 2026	341,584	$	26.00	4.2	$	4,555

*The aggregate intrinsic value of outstanding and exercisable stock options is defined as the difference between the market value of our Company’s common stock on June 30, 2026 of $39.33 and the exercise price multiplied by the number of in-the-money outstanding and exercisable stock options.

The following table summarizes our restricted stock award activity for the six-month period ended June 30, 2026:


					Weighted
			Weighted		Average		Aggregate
		Shares of	Average		Remaining		Intrinsic
		Restricted	Grant Date		Contractual		Value*
Restricted Stock		Stock	Fair Value		Term (In Years)		(In Thousands)
Non-vested - January 1, 2026		120,539	$	31.06
Granted		—		—
Vested		—		—
Forfeited		(3,140)		31.06
Non-vested - June 30, 2026		117,399	$	31.06	3.3	$	4,617

*The aggregate intrinsic value of non-vested restricted stock was calculated using the market value of our Company’s common stock on June 30, 2026 of $39.33 multiplied by the number of non-vested restricted shares outstanding.